I'm not opposed to the 200m additional shares, but I am very skeptical of the ultimate use. Last year I voted against a lot of executive comp, which was passed despite some pretty vocal opposition. After they added to authorized shares last year under the premise of using for trials, they turned around and put 25m on the table for incentive plans, which included sizeable stock awards for Kelly and Nader based on a vesting schedule, not milestones (like getting the drug approved). Some of the questionable hires like Mahboob got nice awards for nothing.

If we're funding trials and operations, fine, but another executive grab at free shares with no approved drug will not sit well.